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INTRODUCTION
Prostatic stromal sarcoma (PSS) is quite rare, comprising 
only 0.1-0.2% of all malignant prostate tumors (1). 
In 1998, Gaudin et al. (2) classified sarcoma-related 
proliferative lesions of the specialized prostatic stroma, 
including prostatic phyllodes tumors, into two subtypes: 
prostatic stromal proliferation of uncertain malignant 
potential and PSS (2, 3). Herein, we present a case of PSS 
in a young man. To the best of our knowledge, only three 
reports of PSS with findings from computed tomography 
(CT) have been reported in the English literature (1, 4, 
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5). However, none of those reports described findings on 
magnetic resonance imaging (MRI). This represents the first 
report in the radiological literature on the MRI appearance 
of PSS.
CASE REPORT
A 26-year-old man presented with a history of dysuria and 
hematuria for about one month. A digital rectal examination 
revealed a huge hard mass with an irregular surface. Serum 
levels of prostate-specific antigen (PSA) were not elevated 
(0.44 ng/mL). Various other tumor markers were also within 
normal limits. MRI was performed using a 1.5-T Signa Excite 
scanner (GE Medical Systems, Milwaukee, WI) and a phased-
array torso coil. T2-weighted fast spin-echo (FSE) imaging 
in the transverse and coronal planes, T2-weighted echo-
planar imaging (EPI) in the transverse plane, T1-weighted 
FSE imaging in the transverse plane, diffusion-weighted 
imaging (DWI) (using b-factors of 0 and 800 s/mm
2) in the 
transverse plane, dynamic contrast-enhanced MRI (DCE-MRI) 
in the transverse plane, and contrast-enhanced T1-weighted 
FSE imaging in the transverse plane were performed. 520
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Fig. 1. Prostatic stromal sarcoma in 26-year-old man.
A. Axial T1-weighted image showing mass located centrally and to right side of prostate with homogeneous slight low signal intensity in 
comparison with left side of prostate (arrows). B. Axial T2-weighted echo-planar image showing multinodular mass (arrows) with irregular 
margins associated with nodular lesions (small arrows) in posterior part of mass, and presenting heterogeneous high signal intensity. Right 
peripheral gland (arrowheads) is compressed by central glandular mass. C-E. Axial dynamic contrast-enhanced MR images at 0 s (C), 30 s (D) 
and 150 s (E) after contrast injection, showing weakly enhanced mass containing non-enhanced cystic areas in central gland (arrows). As right 
peripheral gland shows gradual moderate enhancement (arrowheads), which differs from enhancement in left peripheral gland, tumor invasion 
to right peripheral gland is suggested. F. Axial diffusion-weighted image showing central gland mass (arrows) and right peripheral zone mass 
(arrowheads) as areas of marked high signal intensity. 521
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Data acquisition for DCE-MRI began simultaneously with 
the initiation of intravenous injection of gadopentetate 
dimeglumine (Magnevist; Bayer Schering Pharma, Osaka, 
Japan) at 0.1 mmol/kg body weight within 10 s through a 
peripheral intravenous cannula. This was followed by a 40-
mL flush with saline. Multiphase DCE images (6 phases) 
were obtained every 30 s for 150 s without breath-holding.
MRI revealed an uneven multinodular mass located mainly 
within the central zone of the prostate and extending 
to the right peripheral gland at the bottom level of the 
central gland mass. The mass showed homogeneous low 
signal intensity on T1-weighted imaging (Fig. 1A) and 
heterogeneous high signal intensity with pseudocapsule on 
T2-weighted EPI (Fig. 1B). In DCE-MRI, the central gland 
portion of the mass showed a weak gradual enhancement 
containing cystic areas, whereas the right peripheral gland 
showed a moderate gradual enhancement (Fig. 1C-E). 
DWI showed the prostatic mass as an area of marked high 
signal intensity (Fig. 1F). Coronal T2-weighted imaging 
demonstrated enlarged internal iliac lymph nodes (Fig. 1G).
Transrectal ultrasonography-guided prostate biopsy and 
transurethral resection of prostate were performed. The 
resected specimen predominantly comprised elongated 
ducts and cellular stroma that contained areas of necrosis 
with calcification (Fig. 1H). Hypercellular stroma without 
glands was specifically detected. Although epithelial 
components did not show malignant changes, stromal cells 
showed ovoid, spindle-shaped and hyperchromatic nuclei 
in cellular areas, and spindle-shaped nuclei in myxomatous 
areas. An average of two mitoses per high-powered field was 
counted. Epithelial cells showed positive immunostaining 
for pan-cytokeratin (AE1/AE3, CAM5.2). In stromal cells, 
positive immunostaining was detected for vimentin, CD34, 
and progesterone receptor; whereas, negative results 
were obtained for pan-cytokeratin, CD31, S-100, HHF-35, 
desmin, α smooth muscle actin, MyoD1, c-kit, and estrogen 
receptors. The MIB-1 labeling index was elevated to > 50%. 
Consequently, the tumor was histologically diagnosed as 
PSS (2).
Although the patient was treated by chemotherapy, he 
showed progressive disease with bone, lung, liver, and 
mediastinal lymph node metastases and died seven months 
after admission.
DISCUSSION
Primary prostate sarcomas are rare malignant tumors 
of the prostate gland (1, 2). Leiomyosarcoma is the most 
common histological subtype of prostate sarcoma seen in 
adults (6). Prostate stromal sarcoma is rarer with fewer 
than 30 documented cases (1-5, 7-16). Most patients with 
prostatic sarcoma, including PSS, present with symptoms 
of urethral obstruction (1-3, 5, 6), as in the present case. 
The mass effect of the tumor, mainly located in the central 
gland, probably caused the early onset of symptoms (17). 
In previous reports on PSS, age at diagnosis has ranged 
from 19 to 86 years (mean, 48 years) (1-5, 7-16). PSA 
levels in patients with PSS including the present case 
have been relatively low (0.1-4.5 ng/mL) in comparison 
with prostatic adenocarcinoma (1, 3-5). PSS is often large, 
with most tumors having a diameter > 4 cm (1, 3-5). In 
immunohistochemical studies, PSS are typically positive for 
G H
Fig. 1. Prostatic stromal sarcoma in 26-year-old man.
G. Coronal T2-weighted image showing markedly enlarged lymph nodes near seminal vesicle and separated from prostatic mass (arrow). H. 
Histological findings from transurethral resection of prostate. Low-power views show leaf-like projection of proliferating stroma. Cellular stroma 
contains round and spindle-shaped cells with atypia and mitosis (Hematoxylin & Eosin staining, × 100).522
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vimentin and CD 34, and negative for estrogen receptor and 
HHF-35 (1, 2).
On MRI, a prostatic adenocarcinoma typically demonstrates 
an unidentified area with signal isointensity relative to 
background prostatic structures on T1-weighted imaging; an 
area in the peripheral zone with homogeneous low signal 
intensity with mass effect, or an area in the transition 
zone with homogeneous low signal intensity, ill-defined 
margins, and lack of a capsule, with or without a lenticular 
shape and invasion of anterior fibromuscular stroma on T2-
weighted imaging; an area with focal early enhancement 
on DCE-MRI; and an area with focal high signal intensity 
relative to background prostatic structures on DWI (18-21). 
In the present case, the main tumor in the central gland 
showed a multinodular shape with heterogeneous high 
signal intensity and a low signal intensity pseudocapsule 
on T2-weighted imaging. Furthermore, both areas of tumor 
showed gradual weak enhancement on DCE-MRI. PSS may 
differ from a typical adenocarcinoma with respect to 
shape, vascularity on DCE-MRI, and signal intensity on T2-
weighted imaging, thus reflecting tissue construction and 
cellular structure. Conversely, these PSS findings resemble 
those of leiomyosarcoma and rhabdomyosarcoma, which are 
a more common form of sarcoma involving the prostate (22, 
23). Furthermore, DWI clearly demonstrated both central 
gland and peripheral zone parts of the tumor as showing 
marked high signal intensity, suggesting the usefulness of 
this modality for determining the local extent of the lesion. 
MRI features of PSS have not previously been reported in 
the English literature. However, two reports of MRI findings 
for stromal sarcoma of uterine endometrium by Koyama et 
al. (24) and Ueda et al. (25) demonstrated that stromal 
sarcoma was relatively large and showed heterogeneous 
signal intensity on T2-weighted imaging, heterogeneous 
contrast enhancement of the tumor, marginal nodules, 
multiple nodule formation, hemorrhage, and necrosis in the 
tumor. All these MRI findings except hemorrhage were also 
seen in our case.
MRI findings including T2-weighted imaging, DCE-
MRI, and DWI in the present case seemed to reflect the 
pathological features of PSS, which include aggressive 
tumor growth, greater cellularity, and necrosis with mitotic 
activity.
In the present case, the tumor was mainly located in the 
central gland, and appeared as a signal hypointense mass 
on T1-weighted imaging, and as a heterogeneously signal 
hyperintense multinodular mass on T2-weighted imaging. 
DCE-MRI indicated weak to moderate gradual enhancement 
containing cystic areas. PSS did not resemble prostatic 
adenocarcinoma on MRI, which may thus play a role in 
differentiating PSS from prostatic adenocarcinoma. When 
an adult male shows MRI findings as mentioned above, 
although these imaging findings are not pathognomonic, 
PSS should be included in the differential diagnoses of a 
prostatic adenocarcinoma.
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